Arrowhead Pharmaceuticals, based in Pasadena, California, develops RNA-based therapies targeting intractable diseases, employing 525 staff and featuring 14 clinical-stage investigational medicines across various therapeutic areas. Their TRiMTM platform enables tissue-specific delivery through RNA interference mechanisms.
ARWR filed a patent for "rnai agents for inhibiting influenza viral gene expression, compositions thereof, and methods of use" on Fri, January 13, 2023.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
